These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34542015)

  • 1. Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy.
    Kubo T; Hirohashi Y; Tsukahara T; Kanaseki T; Murata K; Morita R; Torigoe T
    Immunol Med; 2022 Jun; 45(2):108-118. PubMed ID: 34542015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
    Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N; Tanaka R
    Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
    Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
    Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.
    Chhabra N; Kennedy J
    J Med Toxicol; 2021 Oct; 17(4):411-424. PubMed ID: 33826117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis.
    Park R; Lopes L; Saeed A
    Immunotherapy; 2020 Nov; 12(16):1183-1193. PubMed ID: 32878511
    [No Abstract]   [Full Text] [Related]  

  • 7. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach.
    Del Gaudio A; Di Vincenzo F; Petito V; Giustiniani MC; Gasbarrini A; Scaldaferri F; Lopetuso LR
    Inflamm Bowel Dis; 2024 Jun; 30(6):1018-1031. PubMed ID: 37801695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.
    Abdel-Wahab N; Suarez-Almazor ME
    Expert Rev Clin Immunol; 2024 Aug; 20(8):873-893. PubMed ID: 38400840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
    Tang H; Guan M; Sun Z; Bai CM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
    Zhou L; Wei X
    Front Immunol; 2021; 12():701951. PubMed ID: 34504488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors.
    Zhang Y; Cheng S; Zou H; Han Z; Xie T; Zhang B; Dai D; Yin X; Liang Y; Kou Y; Tan Y; Shen L; Peng Z
    Front Cell Infect Microbiol; 2023; 13():1099063. PubMed ID: 37051296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology.
    Hercun J; Vincent C; Bilodeau M; Lapierre P
    Front Immunol; 2022; 13():907591. PubMed ID: 35844534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
    Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
    J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy.
    Zhou N; Velez MA; Owen D; Lisberg AE
    J Natl Compr Canc Netw; 2020 Sep; 18(9):1287-1290. PubMed ID: 32886906
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of B cells in immune-related adverse events following checkpoint blockade.
    Dhodapkar KM; Duffy A; Dhodapkar MV
    Immunol Rev; 2023 Sep; 318(1):89-95. PubMed ID: 37421187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.
    Zhuang J; Du J; Guo X; Zhou J; Duan L; Qiu W; Si X; Zhang L; Li Y; Liu X; Wang H; Zhou D; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):799-804. PubMed ID: 32017466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-resident memory T cells in immunotherapy and immune-related adverse events by immune checkpoint inhibitor.
    Xiong H; Shen Z
    Int J Cancer; 2024 Jul; 155(2):193-202. PubMed ID: 38554117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients.
    Tang SQ; Tang LL; Mao YP; Li WF; Chen L; Zhang Y; Guo Y; Liu Q; Sun Y; Xu C; Ma J
    Cancer Res Treat; 2021 Apr; 53(2):339-354. PubMed ID: 33171025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.